Sterling Capital Management’s Fennec Pharmaceuticals FENC Stock Holding History

Sterling Capital Management’s Portfolio FENC Stock Details FENC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.1K	Sell	102 -642	-86%	-$5.24K	﹤0.01%	3109
2026 Q1	$4.58K	Sell	744 -286	-28%	-$2.21K	﹤0.01%	2774
2025 Q4	$7.93K	Sell	1,030 -168	-14%	-$1.38K	﹤0.01%	2718
2025 Q3	$11.2K	Buy	1,198 +686	+134%	+$5.94K	﹤0.01%	2429
2025 Q2	$4.25K	Buy	512 +178	+53%	+$1.22K	﹤0.01%	2598
2025 Q1	$2.03K	Sell	334 -294	-47%	-$1.89K	﹤0.01%	2592
2024 Q4	$3.97K	Buy	628 +566	+913%	+$2.9K	﹤0.01%	2554
2024 Q3	$310	Buy	+62	New	+$359	﹤0.01%	3023

Other funds holding FENC

Rosalind Advisors Toronto, Ontario, Canada $269M AUM 103.38% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return

SCM

Solas Capital Management Darien, Connecticut $187M AUM 12.91% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIC

AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

PCA

Prospect Capital Advisors Sausalito, California $220M AUM 60.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Sterling Capital Management's FENC Position: Q2 2026 in Review

Sterling Capital Management reduced its Fennec Pharmaceuticals (FENC) stake by 86% in Q2 2026, selling an estimated $5.24K and leaving 102 shares worth $1.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3109.

Sterling Capital Management first reported a position in FENC in Q3 2024 and has held it in 8 quarters since. The position peaked at $11.2K in Q3 2025. 104 funds tracked by Wall St. Rank hold FENC as of Q2 2026.

Sterling Capital Management held 102 shares of Fennec Pharmaceuticals worth $1.1K as of Q2 2026.
Sterling Capital Management sold 642 Fennec Pharmaceuticals shares in Q2 2026, an estimated $5.24K.
Fennec Pharmaceuticals made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #3109 holding.
Sterling Capital Management first reported a position in Fennec Pharmaceuticals in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's Fennec Pharmaceuticals position peaked at $11.2K in Q3 2025.
104 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.